Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
NCT00731224
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
380
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
DRUG:
Rivastigmine transdermal patch
Sponsor
Novartis Pharmaceuticals